Merck built a wall of patents to keep a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

Merck (MRK) closed at $120.15 in the latest trading session, marking a -1.05% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.02%. Elsewhere, the Dow saw an ...

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

Merck and Sanofi are the latest drugmakers to join TrumpRx.gov, offering steep discounts on diabetes, tuberculosis and blood ...

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing ...

The pharmaceutical giant is a standout performer within the health-care sector, and the stock could be poised for a big jump.

By Christy Santhosh March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully reducing bad cholesterol in a late-stage head-to-head trial with other therapies ...

Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...

Merck headquarters in Rahway, NJ. RAHWAY, N.J.- Merck has completed its $10 billion buyout of the British biopharmaceutical company Verona. The deal was first announced in July. It brings the chronic ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on ...